Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Goldman Cuts Burberry; Redburn Cuts HSBC

Fri, 07th Sep 2018 09:33

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:----------FTSE 100----------GOLDMAN CUTS BURBERRY GROUP TO 'NEUTRAL' ('CONVICTION BUY LIST') - TARGET 2536 PENCE----------RBC RAISES BURBERRY GROUP PRICE TARGET TO 1875 (1750) PENCE - 'UNDERPERFORM'----------RBC INITIATES DCC WITH 'OUTPERFORM' - TARGET 9500 PENCE----------RBC CUTS BUNZL PRICE TARGET TO 1800 (1950) PENCE - 'UNDERPERFORM'----------BERENBERG CUTS SHIRE TO 'HOLD' ('BUY') - TARGET 5000 (4500) PENCE----------JPMORGAN RAISES MELROSE INDUSTRIES PRICE TARGET TO 285 (260) PENCE - 'OVERWEIGHT'----------REDBURN CUTS HSBC TO 'SELL' ('NEUTRAL')----------BARCLAYS RAISES ST JAMES'S PLACE PRICE TARGET TO 1456 (1387) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 696 (693) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 2163 (2076) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES LEGAL & GENERAL GROUP PRICE TARGET TO 317 (311) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES DIRECT LINE PRICE TARGET TO 366 (361) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES AVIVA PRICE TARGET TO 610 (581) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES ADMIRAL GROUP PRICE TARGET TO 1997 (1939) PENCE - 'UNDERWEIGHT'----------HSBC RAISES CENTRICA PRICE TARGET TO 142 (130) PENCE - 'REDUCE'----------KEPLER CHEUVREUX RAISES ASTRAZENECA PRICE TARGET TO 6100 (5630) PENCE - 'BUY'----------JEFFERIES CUTS ASTRAZENECA PRICE TARGET TO 5975 (6200) PENCE - 'HOLD'----------JEFFERIES CUTS GLAXOSMITHKLINE PRICE TARGET TO 1725 (1775) PENCE - 'BUY'----------FTSE 250----------JPMORGAN CUTS GO-AHEAD GROUP PRICE TARGET TO 1420 (1421) PENCE - 'UNDERWEIGHT'----------JPMORGAN CUTS WEIR GROUP PRICE TARGET TO 2060 (2200) PENCE - 'OVERWEIGHT'----------BARCLAYS CUTS WEIR GROUP PRICE TARGET TO 2500 (2600) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PHOENIX GROUP PRICE TARGET TO 688 (667) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 693 (667) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES JARDINE LLOYD THOMPSON PRICE TARGET TO 1523 (1495) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES HISCOX PRICE TARGET TO 1427 (1314) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES HASTINGS GROUP PRICE TARGET TO 272 (267) PENCE - 'EQUAL WEIGHT'----------PEEL HUNT RAISES GREENE KING TO 'BUY' ('ADD') - TARGET 700 PENCE----------KEPLER CHEUVREUX RAISES GENUS PRICE TARGET TO 2540 (2470) PENCE - 'HOLD'----------CREDIT SUISSE CUTS WILLIAM HILL PRICE TARGET TO 330 (340) PENCE - 'OUTPERFORM'----------HSBC CUTS WILLIAM HILL PRICE TARGET TO 290 (325) PENCE - 'HOLD'----------OTHER MAIN MARKET AND AIM----------BERENBERG INITIATES GLOBALDATA WITH 'BUY' - TARGET 820 PENCE----------JPMORGAN RAISES REDDE PRICE TARGET TO 207 (197) PENCE - 'OVERWEIGHT'----------PEEL HUNT RESUMES CHEMRING GROUP WITH 'ADD' - TARGET 240 PENCE----------PEEL HUNT RESUMES PAN AFRICAN RESOURCES WITH 'BUY' - TARGET 16 PENCE----------LIBERUM PUTS EI GROUP RATING UNDER REVIEW FROM 'HOLD'----------

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.